Traws Pharma (NASDAQ:TRAW) Trading 0.6% Higher – Here’s What Happened

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) traded up 0.6% during mid-day trading on Monday . The stock traded as high as $1.79 and last traded at $1.66. 277,466 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 439,075 shares. The stock had previously closed at $1.65.

Traws Pharma Price Performance

The company has a market capitalization of $9.24 million, a P/E ratio of -0.01 and a beta of 1.48. The firm has a fifty day moving average price of $1.57 and a 200-day moving average price of $4.20.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Thursday, May 15th. The company reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.04) by $10.13. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million.

Hedge Funds Weigh In On Traws Pharma

Several institutional investors have recently modified their holdings of TRAW. Adage Capital Partners GP L.L.C. purchased a new position in Traws Pharma in the first quarter valued at approximately $759,000. Vestal Point Capital LP lifted its stake in Traws Pharma by 133.3% in the first quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock valued at $402,000 after purchasing an additional 100,000 shares during the last quarter. Millennium Management LLC purchased a new position in Traws Pharma in the fourth quarter valued at approximately $89,000. Alyeska Investment Group L.P. purchased a new position in Traws Pharma in the fourth quarter valued at approximately $1,036,000. Finally, Boothbay Fund Management LLC purchased a new position in Traws Pharma in the fourth quarter valued at approximately $252,000. 7.95% of the stock is owned by institutional investors.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.